

BUSINESS: Berlin based investment company that invests in the German and European medical cannabis industry. Main investment subsidiary, AMP Germany purchases pharmaceutical grade (EU-GMP) cannabis from Canadian licenced producers for import to Germany. AMP Germany sells imported EU-GMP cannabis to pharmaceutical wholesalers in Germany who supply pharmacists.

Recent Developments: In conjunction with CSE listing and de-listing on the TSXV, the company changed its name to AMP German Cannabis Group Inc. from "Chinook Tyee Industry Limited".

Recent Financings: Closed Series A private placement financing raising \$1.5M through the issuance of 10M shares priced at C\$0.15 per share on 12jun19.

2019 Business Objectives: 1. Enter into distribution agreements with German pharmaceutical distributors; 2. Receive a narcotic license in Germany for dealing with cannabis; 3. Invest in Switzerland's CBD medical cannabis industry.

GERMAN MEDICAL CANNABIS INDUSTRY COMMENTS: Since legalization medical cannabis in March 2017, Germany has imported 1,700 kg in 2017 and 2,845 kg in 2018 of EU-GMP medical cannabis(2). In April 2019, Germany announced the successful candidates to cultivate a total of 2,600 kg per year of EU-GMP medical cannabis to three Canadian companies beginning in 2021. In the Company's opinion, until Germany issues more cultivation licenses it will not meet demand and will have to rely on imports to fill the gap. Current supplier to Germany in order of size are Dutch producer, Bedrocan and Canadian producers Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB) and Cronos Group (Nasdaq: CRON). In April 2019, Germany awarded cultivation licenses to Canadian producers, Alphria (NYSE: APHA), Aurora and Wayland Group (CSE: WAYL).

STOCK TRADING INFORMATION (2019)
Q2



Shares outstanding	20,217,796
Fully diluted shares outstanding	21,478,024
High/low (TSXV)	\$0.45/\$0.13
High/low (FSE)	€0.32/€0.06
Market capitalization	\$ 6,100,000
Trading volume (TSXV)	3,005,380
Trading volume (FSE)	166,818

BOARD & MANAGEMENT: Director and CEO: *Alex W. Blodgett* (CDN). Director and President: *Dr. Stefan Feuerstein* (DE). Director: *Claudio Morandi* (CH). Director: *Ken MacLeod* (CDN).

AMP GERMAN CANNABIS GROUP INC. Charlottenstrasse 59, Berlin Germany, 10117 (Representative Office). German Investor Relations: email: investor@amp-eu.de. Canadian Investor Relations: Phone: +236-833-1602, email: investor@amp-eu.com. Social Media: Twitter: @AMP_Cannabis; Reddit: AMP_Cannabis; LinkedIn: AMP German Cannabis; Facebook: @AMPGermanCannabis. Website: www.amp-eu.com

Footnotes

- As of August 20th, 2019
- Source data: 2019 Marijuana Business Daily Report: Medical Cannabis in Europe, The Market & Opportunities

TSX Venture Exchange (TSXV) stock chart from January to August 15 2019

SHARE OWNERSHIP (Pie Chart)

SHARE OWNERSHIP

	Shares	%
Insiders	6,801,692	34%
Series A (less Insiders)	7,323,158	36%
Free float	6,092,946	30%

CAPITAL STRUCTURE

	Shares	Ex Price	Expiry Date
Shares outstanding	20,217,796	-	-
Stock options	1,020,000	\$0.15	11-Oct-19
Finders warrants	240,228	\$0.15	11-Dec-19
Fully diluted shares outstanding	21,478,024	-	-

